Arrowhead

Arrowhead Pharmaceuticals Reports Fiscal 2024 First Quarter Results

Retrieved on: 
Dienstag, Februar 6, 2024
Infectious Diseases, Diabetes, Genetics, Clinical Trials, Cardiology, Biotechnology, Health, Pharmaceutical, Oncology, DSM-IV codes, CTA, Obesity, Retirement, Patient, PIN, Head, IgA nephropathy, Marketing, Idiopathic pulmonary fibrosis, RNA interference, GLP, ARO, Arrowhead, Identified, Webcast, Liver, Pharmacy, Toxicology, Completeness, Pharmaceutical industry

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2024 first quarter ended December 31, 2023.

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2024 first quarter ended December 31, 2023.
  • The Company is hosting a conference call today, February 6, 2024, at 4:30 p.m.
  • A replay of the webcast will be available approximately two hours after the conclusion of the call.
  • Once registered, you will receive the dial-in number and a personalized PIN code that will be required to access the call.

Jim Davis, Renowned Geologist and the Leading Authority on Copper Mountain, Joins Myriad's Technical Committee

Retrieved on: 
Donnerstag, Januar 18, 2024
Neutron, Arrowhead, Encore, COP28, Uranium, Senate, Myriad, UN, Mining, University, Qualified person (European Union), Union Pacific Railroad, MIT, Human body temperature, Gold, ISR, Congress, International Atomic Energy Agency, Nabarlek, SCI, News, National instrument, Uranium mining

Much of this work was led by Jim Davis, and we are delighted he is joining our Technical Committee.

Key Points: 
  • Much of this work was led by Jim Davis, and we are delighted he is joining our Technical Committee.
  • His first discovery as a young geologist was the Arrowhead Uranium Mine located at the centre of Copper Mountain (see Figure 1 above).
  • Mr. Davis subsequently led Union Pacific's extensive exploration at Copper Mountain, leading to the discovery of the Canning Deposit and several others in the district.
  • He was Chief Consulting Geologist for Neutron Energy (now part of enCore), a previous owner of part of Copper Mountain.

Aduro Clean Technologies Presents at CEM AlphaNorth Capital Event and Extends Engagement with Arrowhead Business and Investment Decisions

Retrieved on: 
Dienstag, Januar 16, 2024
ACT, Arrowhead, Investment decisions, Chemistry, CEM, Oil, Capital, Marketing

During the event, Aduro will conduct one-on-one meetings with interested investors and other stakeholders.

Key Points: 
  • During the event, Aduro will conduct one-on-one meetings with interested investors and other stakeholders.
  • The Company has also extended its engagement with Arrowhead Business and Investment Decisions, LLC (“Arrowhead”), originally announced on May 4, 2023 , regarding the provision of investor relations services to the Company.
  • The Company is pleased to be participating in the CEM AlphaNorth Capital Event and to have the opportunity to showcase its recent achievements and discuss future plans with investors.
  • The Company is also pleased to announce that it has extended its marketing and investor relations agreement with Arrowhead.

REI Co-op to open 10 stores in 2024 to better serve outdoor communities

Retrieved on: 
Mittwoch, Januar 10, 2024
Camping, Arrowhead, Black Friday, Adventure, REI, The, Cooperative, Running, The Co-operative Group, Retirement, Organization, St. George Place, Houston, Real estate

SEATTLE, Jan. 10, 2024 /PRNewswire/ -- Specialty outdoor retailer REI Co-op announced expansion plans to open 10 new stores in 2024 to better serve its members and outdoor community. Locations have been finalized for summer 2024 openings in Glendale, Arizona and Rancho Mirage, California. A store in St. George, Utah will open in fall 2025.

Key Points: 
  • Retailer expands to Glendale, Arizona and Rancho Mirage, California in summer 2024 and St. George, Utah in fall 2025
    SEATTLE, Jan. 10, 2024 /PRNewswire/ -- Specialty outdoor retailer REI Co-op announced expansion plans to open 10 new stores in 2024 to better serve its members and outdoor community.
  • REI will open 10 stores in 2024, including:
    The co-op will announce details of three additional stores opening this year as contracts are finalized.
  • As a community-supported nonprofit, the REI Fund is fueled by donations from REI members, customers, employees, foundations and corporate partners – including REI Co-op.
  • Of that total, more than 200 of the grantees were local organizations championed by REI employees who work in-store.

Arrowhead Pharmaceuticals Closes Underwritten Offering with Gross Proceeds of $450.0 Million

Retrieved on: 
Freitag, Januar 5, 2024
Biotechnology, Infectious Diseases, Health, Genetics, Pharmaceutical, Research, RBC Capital Markets, Jefferies, Arrowhead, Sale, BofA Securities

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that on January 5, 2024, it closed the previously announced underwritten registered offering of 15,790,000 shares of its common stock, par value $0.001 per share (“Common Stock”).

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that on January 5, 2024, it closed the previously announced underwritten registered offering of 15,790,000 shares of its common stock, par value $0.001 per share (“Common Stock”).
  • The offering was priced at $28.50 per share, and the company received gross proceeds of approximately $450.0 million, before deducting underwriting discounts, commissions and other offering expenses payable by the company.
  • Jefferies, BofA Securities and TD Cowen acted as bookrunning managers for the offering.
  • Arrowhead intends to use the net proceeds from this offering for research and development, general corporate expenses and working capital needs.

Arrowhead Pharmaceuticals Announces Pricing of $450.0 Million Underwritten Offering of Common Stock

Retrieved on: 
Mittwoch, Januar 3, 2024
Oncology, Health, Hospitals, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Telephone, Lexington Avenue, Sale, Jefferies Group, Research, Form, Attention, Arrowhead, Jefferies, BofA Securities, Madison Avenue, Security (finance), Life insurance

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the pricing of an underwritten registered offering of 15,790,000 shares of its common stock, par value $0.001 per share (“Common Stock”), offered at a price of $28.50 per share, before underwriting discounts.

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the pricing of an underwritten registered offering of 15,790,000 shares of its common stock, par value $0.001 per share (“Common Stock”), offered at a price of $28.50 per share, before underwriting discounts.
  • The offering is expected to close on or about January 5, 2024, subject to customary closing conditions.
  • Gross offering proceeds will be approximately $450.0 million, before deducting underwriting discounts and commissions and estimated offering expenses.
  • Arrowhead intends to use the net proceeds from this offering for research and development, general corporate expenses and working capital needs.

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-CFB for Complement Mediated Kidney Disease

Retrieved on: 
Donnerstag, Dezember 21, 2023
Health, Medical Devices, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Committee, RNA, Liver, RNA interference, System, CFB, Kidney, Kidney disease, Glomerulonephritis, Translational medicine, Arrowhead Pharmaceuticals, Arrowhead, MBA, Clinical trial, Pharmacokinetics, Complement factor B, Ethics committee, Discovery, Safety, Patient, Pharmaceutical industry

Additionally, ARO-CFB may have clinical applications in non-renal diseases involving complement activation.

Key Points: 
  • Additionally, ARO-CFB may have clinical applications in non-renal diseases involving complement activation.
  • ARO-CFB is designed to reduce hepatic expression of complement factor B (CFB), which plays an important regulatory role in amplifying complement alternative pathway activation and has been identified as a promising therapeutic target.
  • James Hamilton, M.D., MBA, Chief of Discovery and Translational Medicine at Arrowhead, said: “IgAN is the most common glomerular disease worldwide, accounting for up to 40% of all cases of glomerulonephritis.
  • Pending clearance, Arrowhead intends to proceed with AROCFB-1001, a Phase 1/2a dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-CFB in up to 66 healthy volunteers and patients with complement mediated kidney disease.

Mama Kelce’s Cookies Will Be Sold at Chiefs’ and Eagles’ NFL Christmas Games to Benefit Operation Breakthrough and the Eagles Autism Foundation

Retrieved on: 
Mittwoch, Dezember 20, 2023
Sports, Football, Health, Food, Beverage, Philanthropy, Foundation, Retail, Other Health, Philadelphia Eagles, Aramark, Sale, Operation Breakthrough, Lincoln Financial Field, Holiday, Organic, Sport, Eagle, Love, Arrowhead Stadium, NFL, Super Bowl, Arrowhead, Bowl game, Kansas City Chiefs, Operation, Life, Video game

The Aramark culinary teams will freshly prepare Mama Kelce’s cookie recipe for fans.

Key Points: 
  • The Aramark culinary teams will freshly prepare Mama Kelce’s cookie recipe for fans.
  • All proceeds from cookie sales will benefit Operation Breakthrough based in Kansas City and the Eagles Autism Foundation based in Philadelphia, and Aramark will match the donation to each organization 1:1.
  • “I am so excited to work with Aramark to bring my cookies to Chiefs’ and Eagles’ fans on Christmas day,” said Donna Kelce.
  • “In this season of giving, it means so much to raise money for two great charities through an old-fashioned bake sale.

Arrowhead Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Mittwoch, Dezember 20, 2023
Biotechnology, Pharmaceutical, Genetics, Health, Conference, Arrowhead

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to present at the upcoming 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024, at 8:15 a.m. PT.

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to present at the upcoming 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024, at 8:15 a.m. PT.
  • A webcast of the presentation may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.

2025 UX 300h BRINGS MORE POWER TO THE STREETS

Retrieved on: 
Mittwoch, Dezember 20, 2023
Caviar, Shock, Crosswind, VSC, LDA, Aluminium, Apple, Premium, ACA, Smartphone, Radar, Acceleration, Adaptive cruise control, Base, Multimedia, LTA, LED, Electronic stability control, Macpherson, USB, Signature, Human, Redline, Arrowhead, Interface, Safety, App, Agility, FWD, E-four, Intelligence, Android, Tablet, The White Pearl, AWD, RSA, Lapis lazuli, AVS, PCS, MID, Sale, Glass, Lexus, Eminent, POI, Element, PDA, 8-way, Road

A new hybrid transaxle and lightweight lithium-ion battery contribute to the higher output with the 2025 UX 300h, providing more responsive performance.

Key Points: 
  • A new hybrid transaxle and lightweight lithium-ion battery contribute to the higher output with the 2025 UX 300h, providing more responsive performance.
  • Only offered with a hybrid powertrain in the U.S., the 2025 UX 300h supports Lexus' work towards the realization of a carbon-neutral society.
  • Pricing for the 2025 Lexus UX 300h will be announced in the new year with the vehicle going on sale shortly after.
  • The 2025 Lexus UX 300h is offered in eight different models, including F SPORT Design and F SPORT Handling.